Aktis Oncology Inc. (NASDAQ: AKTS) appointed Glenn Gormley, MD, PhD, as an independent director to its board of directors and co-chair of the company's newly established Science and Technology Committee.

Gormley brings more than three decades of biopharmaceutical leadership experience across research and development, executive leadership, and board service. He most recently served as Senior Executive Officer and Global Head of Research and Development at Daiichi Sankyo Co., Ltd., and as Executive Chairman and President of Daiichi Sankyo, Inc.

In his previous roles, Gormley led global R&D strategy and oversaw development of a broad pipeline, including the build-out of Daiichi Sankyo's antibody drug conjugate platform. He previously held senior leadership positions at AstraZeneca as Chief Medical Officer and at Novartis as Global Head of Clinical Development and Medical Affairs. Earlier in his career, he held senior clinical development roles at Merck.

Gormley holds an MD and PhD from the University of Chicago and completed training at UCLA and New York University, leading to board certification in pediatrics and pediatric endocrinology.

Concurrent with Gormley's appointment, current board members Helen Kim and Oleg Nodelman plan to step down from Aktis' board of directors, effective May 20, 2026, according to the company's press release.

Aktis Oncology is a clinical-stage oncology company focused on targeted radiopharmaceuticals. The company's most advanced pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4 across multiple tumor types. Its second pipeline program, AKY-2519, targets B7-H3 expressing tumors.

The company has a strategic collaboration with Eli Lilly and Company to develop novel radioconjugates outside of Aktis' proprietary pipeline.